Navigation Links
New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
Date:11/13/2007

-- Data Presented at Anti-Angiogenesis Conference Shows R84, the Selective

Human Anti-VEGF Antibody Developed by Peregrine in Association with Affitech, Is Equivalent to Avastin in Inhibiting Growth of Established

Tumors in a Preclinical Breast Cancer Model --

-- R84 Is Being Advanced as a Potential Clinical Candidate --

BOSTON and TUSTIN, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported that preclinical data presented at IBC's 5th Annual International Anti-Angiogenesis Conference showed that its anti-VEGF antibody R84 was as effective as Avastin(R) (bevacizumab) in inhibiting tumor growth in a mouse model of human breast cancer. R84 is a selective, fully human monoclonal antibody that blocks the cancer-promoting agent vascular endothelial growth factor (VEGF). R84 selectively blocks VEGF from binding only to VEGF receptor 2 (VEGFR2), while non-selective agents such as Avastin block binding to both VEGFR2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents may have potential advantages over non-selective approaches and Peregrine is now assessing R84 as a candidate for clinical development. R84 is a product of the collaboration between Peregrine and antibody developer Affitech AS of Oslo, Norway.

The data demonstrating the potential anti-cancer efficacy of R84 in xenograft models of human cancer was part of a presentation by Dr. Rolf Brekken, assistant professor of surgery and pharmacology and Effie Marie Cain Scholar in Angiogenesis Research at UT Southwestern Medic
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Video: New Research Discovers Independent Brain Networks Control Human Walking
9. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
10. Enrollment Begins on Human PK Study for Medidur(TM) FA
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  The preclinical contract research organization ... testing of drugs and safety testing of medical devices, ... of Preclinical Studies, presented at this week,s annual meeting ... (ARVO) in Denver, CO. The ... of a Novel, Cross-Linked, Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) ...
(Date:5/5/2015)... and NIJMEGEN, the Netherlands ... medical device company developing lower esophageal sphincter (LES) ... long-term, 3-year, positive safety and efficacy results. The ... of both heartburn and regurgitation and the "gold-standard" ... test) with near-complete elimination of dependence on daily ...
(Date:5/5/2015)... and Markets ( http://www.researchandmarkets.com/research/9pthtm/home_healthcare ) has announced ... - Forecast to 2020" report to their offering. ... reach more than $300+ billion growing at a CAGR ... market is expected to grow at a faster rate ... gaining a tremendous attention over hospitals for the sophistication, ...
Breaking Medicine Technology:Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3Global Home Healthcare Global Market 2015 - Forecast to 2020 for the $300 Billion Market 2
... More Effective Monitor Than, Hemoglobin A1C of Exenatide, Sitagliptin, ... ... 7 GlycoMark, Inc. announced today,results from the ongoing ... a better reflection of glucose, particularly after-meal,glucose levels, than ...
... June 6 , - "ADVANCE Results go ... world,s largest ever study of diabetes treatments,show that ... and other drugs as required, protects patients against ... reduces,the risk of kidney disease by one-fifth. Presented ...
Cached Medicine Technology:DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 2DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 3The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
(Date:5/5/2015)... Private equity consultant and international research ... that its dental stem cell biobank project, Provia ... April, 2015 –and posted yet another exciting record. This ... and represents a significant 54% increase over last April ... is conducted via the Store-A-Tooth brand. The company has ...
(Date:5/5/2015)... 2015 NCPDP announced today that ... program establishes a three-year commitment of strategic support for ... Elite Partners. “AmerisourceBergen has supported our multi-stakeholder forum over ... “and this is a wonderful continuation and expansion of ... trace AmerisourceBergen back to our very first Board of ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 Leveraging ... Clinic in Greece, an experienced team of fertility ... of infertility for patients around the globe. , “We’re ... VisitandCare.com. Greece unquestionably remains a global leader in reproductive ... and hard-working fertility specialists in the world who play ...
(Date:5/5/2015)... New York, New York (PRWEB) May 05, ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) filed on ... cardiovascular complications due to their use of ... forward in the federal multidistrict litigation underway ... Illinois. According to court documents dated May ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Baptist Medical ... Commission on Cancer (CoC) of the American College of ... program must meet more than 30 Commission on Cancer ... a survey process, and maintain levels of excellence in ... When patients choose to seek care locally at a ...
Breaking Medicine News(10 mins):Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4
... ... ... ... ...
... ... ... , ... , , , , ...
... ... ... , ... , , ...
... 2010 winners of the Young Investigator Award. This ... individuals within 5 years of receiving doctoral degrees who ... Biology 2010 meeting in Anaheim in April 2010. ... by a committee on the basis of originality and importance ...
... ... of the Center for Quality Growth and Regional Development at Georgia Institute of Technology, ... Forum: Livability and Sustainable Communities – Taking Action for a Clean Energy Future. ... Atlanta, Ga. (PRWEB) ...
... ... ... ... ...
Cached Medicine News:Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 2Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 3Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 4Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 5Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 6Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 2Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 3Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 4Health News:89 Women Celebrate Mardi Gras with Mammograms 2Health News:89 Women Celebrate Mardi Gras with Mammograms 3Health News:SEBM Young Investigator Awards for 2010 2Health News:Dr. Catherine Ross to Participate Today in White House Clean Energy Economy Forum 2Health News:Dr. Catherine Ross to Participate Today in White House Clean Energy Economy Forum 3Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 2Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 3Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 4Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 5Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 6Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 7
... MB Grade PRODUCT SPECIFICATIONS Form: Granular, free flowing powder ... 0.12 Gel Point (3%): less than or equal ... equal to 76C Gel Strength (3%): greater than or ... greater than or equal to 1000 gm/cm 2 ...
... chloride (Cl) ≤ 500 mg/kg sulfate (SO 4 ) ... Cd ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ... 10 mg/kg K ≤ 50 mg/kg Mg ≤ 50 ... Ni ≤ 5 mg/kg Pb ≤ 5 mg/kg Zn ...
... Application: Forms strong flexible ... ( ID clarifier: mixture of ... 3:1 Solubility: water 10 mg/mL, ... grade: for molecular biology MP: ...
Inquire...
Medicine Products: